Halozyme Therapeutics, Inc. (HALO) Tops Q3 EPS by 9c, Sales Beat Expectations
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $111.45 --0%
EPS Growth %: +30.8%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
MLKN, KBH, WOR, More
EPS Growth %: +30.8%
Financial Fact:
Revenues under collaborative agreements: 5.49M
Today's EPS Names:
MLKN, KBH, WOR, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q3 EPS of $0.05, $0.09 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $22.9 million versus the consensus estimate of $19.25 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Halozyme prices $1.3B convertible notes offering due 2033
- Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss of $0.75/sh
- Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
